Trial Profile
The effect of Anti-VEGF treatments of neovascular,exudative and inflammatory eye diseases
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Corneal disorders; Glaucoma; Macular degeneration; Retinal detachment; Uveitis
- Focus Therapeutic Use
- 20 May 2016 New trial record